Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Beyond China and Japan: How biopharma is expanding rare disease access across Asia-Pacific
Of the 400 million patients worldwide diagnosed with rare diseases, about 250 million of them live in North and Southeast Asia1. | While the demand in Asia-Pacific clearly exists, getting approved therapies into these markets is difficult without local support.
TL;DRAI
250M rare disease patients in Asia-Pacific lack approved therapies; DKSH enables biopharma entry through platform addressing regulatory and logistics complexity. Regional partnership reduces barriers, enabling multi-country expansion while managing compliance, reimbursement, and cold chain logistics.
1,285 words~6 min read
